[VIRTUAL] Targeting Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases
Time: 2:30 pm
day: Day Two
Details:
- Amplia’s opportunity with AMP945 a FAK inhibitor for combination therapies
- Preclinical data demonstrating FAK’s role modulating the tumour and in the tumour environment
- Clinical evidence gathered so-far that supports progression of AMP945 combination therapy in patients with advanced pancreatic cancer
